- Home
- APGE vs PRCT Comparison
APGE vs PRCT Comparison
Compare APGE & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- PRCT
- Stock Information
- Founded
- APGE 2022
- PRCT 2009
- Country
- APGE United States
- PRCT United States
- Employees
- APGE N/A
- PRCT N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- PRCT Medical Specialities
- Sector
- APGE Health Care
- PRCT Health Care
- Exchange
- APGE Nasdaq
- PRCT Nasdaq
- Market Cap
- APGE 2.0B
- PRCT 2.1B
- IPO Year
- APGE 2023
- PRCT 2021
- Fundamental
- Price
- APGE $37.63
- PRCT $37.28
- Analyst Decision
- APGE Strong Buy
- PRCT Buy
- Analyst Count
- APGE 5
- PRCT 8
- Target Price
- APGE $95.40
- PRCT $70.00
- AVG Volume (30 Days)
- APGE 465.5K
- PRCT 962.8K
- Earning Date
- APGE 11-11-2025
- PRCT 10-27-2025
- Dividend Yield
- APGE N/A
- PRCT N/A
- EPS Growth
- APGE N/A
- PRCT N/A
- EPS
- APGE N/A
- PRCT N/A
- Revenue
- APGE N/A
- PRCT $274,950,000.00
- Revenue This Year
- APGE N/A
- PRCT $48.38
- Revenue Next Year
- APGE N/A
- PRCT $30.87
- P/E Ratio
- APGE N/A
- PRCT N/A
- Revenue Growth
- APGE N/A
- PRCT 55.71
- 52 Week Low
- APGE $26.20
- PRCT $36.90
- 52 Week High
- APGE $63.50
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- APGE 50.77
- PRCT 39.66
- Support Level
- APGE $36.01
- PRCT $36.90
- Resistance Level
- APGE $37.97
- PRCT $39.40
- Average True Range (ATR)
- APGE 1.66
- PRCT 1.88
- MACD
- APGE 0.02
- PRCT 0.37
- Stochastic Oscillator
- APGE 56.28
- PRCT 6.87
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.